A5059647166- Urinary Bladder and Prostate Research
- Prostate Cancer Diagnosis and Treatment
- Pelvic floor disorders treatments
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Urological Disorders and Treatments
- Kidney Stones and Urolithiasis Treatments
- Urologic and reproductive health conditions
- Urinary and Genital Oncology Studies
- Pediatric Urology and Nephrology Studies
- Ureteral procedures and complications
- Urinary Tract Infections Management
- Renal cell carcinoma treatment
- Advanced Radiotherapy Techniques
- Immune Cell Function and Interaction
- Testicular diseases and treatments
- Hormonal and reproductive studies
- Cancer Immunotherapy and Biomarkers
- Anesthesia and Pain Management
- Cancer, Hypoxia, and Metabolism
- Multiple and Secondary Primary Cancers
- Cancer, Lipids, and Metabolism
- Hepatocellular Carcinoma Treatment and Prognosis
- Myofascial pain diagnosis and treatment
- T-cell and B-cell Immunology
University of St. Gallen
2016-2025
Kantonsspital St. Gallen
2014-2025
Australasian Leukaemia and Lymphoma Group
2024
Klinik und Poliklinik für Urologie
2022
Amsterdam University Medical Centers
2020
Monash University
2020
Paul Scherrer Institute
2020
Institute of Immunology
2012
University of Zurich
1996-2011
Hospital Base
2010
<h3>Abstract</h3> <h3>Objective</h3> To compare prostatic artery embolisation (PAE) with transurethral resection of the prostate (TURP) in treatment lower urinary tract symptoms secondary to benign hyperplasia terms patient reported and functional outcomes. <h3>Design</h3> Randomised, open label, non-inferiority trial. <h3>Setting</h3> Urology radiology departments a Swiss tertiary care centre. <h3>Participants</h3> 103 patients aged ≥40 years refractory were randomised between 11 February...
The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or standard-of-care radiotherapy (RT) is not well documented. Furthermore, no clinical trial has assessed the role RT in node-positive (N+) M0 disease. STAMPEDE Trial includes such individuals, allowing an exploratory multivariate analysis impact radical RT.
Prostatic artery embolisation (PAE) for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction (LUTS/BPO) still remains under investigation. To compare efficacy and safety PAE transurethral resection prostate (TURP) in LUTS/BPO at 2 yr follow-up. A randomised, open-label trial was conducted. There were 103 participants aged ≥40 with refractory LUTS/BPO. versus TURP. International Prostate Symptoms Score (IPSS) other questionnaires, functional measures,...
Abstract Molecular markers reliably predicting failure or success of Bacillus Calmette‐Guérin (BCG) in the treatment nonmuscle‐invasive urothelial bladder cancer (NMIBC) are lacking. The aim our study was to evaluate value cytology and chromosomal aberrations detected by fluorescence situ hybridization (FISH) BCG therapy. Sixty‐eight patients with NMIBC were prospectively recruited. Bladder washings collected before after instillation analyzed conventional multitarget FISH assay (UroVysion®,...
Sacral neuromodulation is well established in the treatment of refractory, non-neurogenic lower urinary tract dysfunction, but its efficacy and safety patients with dysfunction neurological origin unclear. Only few case series have been reported for multiple sclerosis. We prospectively evaluated sacral Seventeen (13 women, 4 men) treated refractory neurogenic caused by sclerosis were enrolled (2007–2011). Patients had to stable disease confirmed dysfunction. Voiding variables, adverse...
Objectives To identify predictors for different treatment outcomes after prostatic artery embolization (PAE) in the of lower urinary tract symptoms secondary to benign hyperplasia. Patients and Methods A post hoc analysis data derived from 48 patients undergoing PAE a randomized, open‐label, non‐inferiority trial was performed. Relative changes International Prostate Symptoms Score (IPSS), absolute maximum flow rate (Q max ), relative magnetic resonance imaging‐assessed prostate volume...
BACKGROUND: Neurogenic lower urinary tract dysfunction (NLUTD) is a highly prevalent and disabling condition; nevertheless, standard treatments often remain unsatisfactory. Sacral neuromodulation (SNM) well-established therapy for non-NLUTD, but there lack of randomized controlled trials to show benefit in patients with NLUTD. METHODS: For this sham-controlled, double-blind, multicenter trial, refractory NLUTD (and intended SNM) were recruited at four Swiss SNM referral centers. After lead...
To assess the economic burden of temporary ureteral stenting.The German version stent symptom questionnaire was completed by 74 patients with unilateral inserted indwelling stents. Cost accounting performed considering costs stents, drugs, consultation healthcare professionals, hospitalization, extraction and work incapacity due to stent-related problems.Total arising from problems amounted US dollars (USD) 133,355, median USD 455 (113-11,948) for entire time, 15 (4-398) per patient day....